Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.
Srinivas N, Peiffer L, Horny K, Lei KC, Buus TB, Kubat L, Luo M, Yin M, Spassova I, Sucker A, Farahpour F, Kehrmann J, Ugurel S, Livingstone E, Gambichler T, Ødum N, Becker JC. Srinivas N, et al. Among authors: livingstone e. Front Oncol. 2024 Aug 7;14:1408614. doi: 10.3389/fonc.2024.1408614. eCollection 2024. Front Oncol. 2024. PMID: 39169943 Free PMC article.
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Egberts F, Gutzmer R, Ugurel S, Becker JC, Trefzer U, Degen A, Schenck F, Frey L, Wilhelm T, Hassel JC, Schadendorf D, Livingstone E, Mauch C, Garbe C, Berking C, Rass K, Mohr P, Kaehler KC, Weichenthal M, Hauschild A. Egberts F, et al. Among authors: livingstone e. Ann Oncol. 2011 Jul;22(7):1667-1674. doi: 10.1093/annonc/mdq648. Epub 2011 Jan 10. Ann Oncol. 2011. PMID: 21220519 Free article. Clinical Trial.
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Zimmer L, et al. Among authors: livingstone e. J Clin Oncol. 2012 Jul 1;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614973 Free PMC article.
Conjunctival melanomas harbor BRAF and NRAS mutations--response.
Griewank KG, Westekemper H, Schilling B, Livingstone E, Schimming T, Sucker A, Hillen U, Steuhl KP, Zimmer L, Schadendorf D. Griewank KG, et al. Among authors: livingstone e. Clin Cancer Res. 2013 Nov 15;19(22):6331-2. doi: 10.1158/1078-0432.CCR-13-2368. Epub 2013 Oct 29. Clin Cancer Res. 2013. PMID: 24170549 No abstract available.
Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG. Scholz SL, et al. Among authors: livingstone e. Oncotarget. 2015 Sep 22;6(28):25868-82. doi: 10.18632/oncotarget.4665. Oncotarget. 2015. PMID: 26327518 Free PMC article.
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S, Höfer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, Ugurel S, Roesch A, Livingstone E, Schilling B, Franklin C. Herz S, et al. Among authors: livingstone e. Eur J Cancer. 2016 Nov;67:66-72. doi: 10.1016/j.ejca.2016.07.026. Epub 2016 Sep 8. Eur J Cancer. 2016. PMID: 27614165
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL, Möller I, Reis H, Süßkind D, van de Nes JAP, Leonardelli S, Schilling B, Livingstone E, Schimming T, Paschen A, Sucker A, Murali R, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG. Scholz SL, et al. Among authors: livingstone e. Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3464-3470. doi: 10.1167/iovs.17-21838. Invest Ophthalmol Vis Sci. 2017. PMID: 28700778
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D. Ugurel S, et al. Among authors: livingstone e. Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735071 No abstract available.
199 results